Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
This Notice of Funding Opportunity (NOFO) supports the translation of genome editing and other biologic therapies for Alzheimer's Disease-Related Dementias (ADRD). The program spans the full translational pipeline, from therapeutic lead optimization and drug product development through IND-enabling studies and early clinical evaluation. Supported activities may include optimization of editing constructs and delivery systems; assessment of bioactivity, target engagement, durability, pharmacokinetics, and bioavailability; demonstration of in vivo efficacy; execution of safety pharmacology and toxicology studies; and development of scalable manufacturing processes, formulation strategies, and quality attributes aligned with regulatory expectations.
ADRD include Frontotemporal Dementia (FTD); Lewy Body Dementias (LBD), including Dementia with Lewy Bodies (DLB) and Parkinson's Disease Dementia (PDD); Vascular Contributions to Cognitive Impairment and Dementia (VCID); and Multiple Etiology Dementias (MED).
Histórico de alterações
First seen 28 Sept 2026, last checked 22 Nov 2026. 20 recorded versions.
- 04 Nov 2026 · 34a93931c23d
- 22 Oct 2026 · e2364c379dc8
- 22 Oct 2026 · d50d4aa626a4
- 21 Oct 2026 · 5682a2adf183
- 20 Oct 2026 · e40bed43426e
- 19 Oct 2026 · ff716d72065a
- 18 Oct 2026 · 87a380c58909
- 17 Oct 2026 · 88f5bdb0b907
- 16 Oct 2026 · 9e8f655a75df
- 15 Oct 2026 · 5682a2adf183
- 14 Oct 2026 · 7ce7902bb173
- 13 Oct 2026 · b70ff8d3d0c0
- 12 Oct 2026 · 3f2ac9b8e863
- 11 Oct 2026 · 704220cdde7b
- 10 Oct 2026 · b295be2b9047
- 09 Oct 2026 · 00f24564712f
- 08 Oct 2026 · 82381e4cefa7
- 07 Oct 2026 · a5edf3caf3bc
- 06 Oct 2026 · 134364f75c14
- 05 Oct 2026 · dc65be088c3e